PPH
VanEck Pharmaceutical ETF
PPH
VanEck Pharmaceutical ETF
-
NAV$109.58
as of September 10, 2026 -
YTD RETURNS7.74%
as of September 10, 2026 -
Total Net Assets$995.86M
as of September 10, 2026 -
Total Expense Ratio0.36%
-
Inception Date12/20/2011
Overview
Why PPH
- Highly Liquid CompaniesTracks the largest most liquid pharmaceutical companies
- Industry LeadersFavors established industry leaders with meaningful scale
- Global ScopeProvides exposure to U.S. and international equities for global industry representation
VanEck Pharmaceutical ETF (PPH®) seeks to replicate as closely as possible, before fees and expenses, the price and yield performance of the MVIS® US Listed Pharmaceutical 25 Index (MVPPHTR), which is intended to track the overall performance of companies involved in pharmaceuticals, including pharmaceutical research and development as well a production, marketing and sales of pharmaceuticals.
Performance
Average Annual Total Returns* (%)
| 1 MO | 3 MO | YTD | 1 YR | 3 YR | 5 YR | 10 YR | LIFE 12/20/11 | |
|---|---|---|---|---|---|---|---|---|
| PPH (NAV) | 2.45 | 8.50 | 11.15 | 29.87 | 13.65 | 10.41 | 8.78 | 10.31 |
| PPH (Market Price) | 2.43 | 8.57 | 11.13 | 29.92 | 13.65 | 10.41 | 8.79 | 10.39 |
| MVIS US Listed Pharmaceutical 25 Index | 2.46 | 8.50 | 10.94 | 29.69 | 13.30 | 10.05 | 8.53 | 10.12 |
| 1 MO | 3 MO | YTD | 1 YR | 3 YR | 5 YR | 10 YR | LIFE 12/20/11 | |
|---|---|---|---|---|---|---|---|---|
| PPH (NAV) | 4.42 | 5.83 | 6.97 | 27.15 | 13.83 | 10.55 | 8.46 | 10.15 |
| PPH (Market Price) | 4.40 | 6.13 | 6.86 | 27.12 | 13.83 | 10.52 | 8.46 | 10.22 |
| MVIS US Listed Pharmaceutical 25 Index | 4.38 | 5.74 | 6.73 | 26.87 | 13.35 | 10.15 | 8.20 | 9.95 |
Holdings
Book a 15-minute call to learn more about the holdings.
Daily Holdings (%) as of 09/10/2026
Download XLS|
Ticker
|
Holding Name |
% of Net Assets
|
Market Value (US$)
|
|---|---|---|---|
|
LLY |
Eli Lilly & Co |
18.92 |
188,378,758 |
|
MRK |
Merck & Co Inc |
11.07 |
110,264,534 |
|
NVS |
Novartis Ag |
9.31 |
92,698,777 |
|
PFE |
Pfizer Inc |
5.17 |
51,469,258 |
|
BMY |
Bristol-Myers Squibb Co |
4.94 |
49,174,455 |
|
NVO |
Novo Nordisk A/S |
4.92 |
48,989,820 |
|
MCK |
Mckesson Corp |
4.80 |
47,792,821 |
|
ABBV |
Abbvie Inc |
4.63 |
46,104,510 |
|
JNJ |
Johnson & Johnson |
4.56 |
45,418,801 |
|
GSK |
Gsk Plc |
4.05 |
40,331,730 |
|
SNY |
Sanofi Sa/France |
4.00 |
39,875,489 |
|
COR |
Cencora Inc |
3.80 |
37,853,806 |
|
AZN |
Astrazeneca Plc |
3.64 |
36,280,585 |
|
TEVA |
Teva Pharmaceutical Industries Ltd |
3.28 |
32,628,596 |
|
TAK |
Takeda Pharmaceutical Co Ltd |
3.24 |
32,265,844 |
|
HLN |
Haleon Plc |
3.05 |
30,375,576 |
|
ZTS |
Zoetis Inc |
2.13 |
21,162,114 |
|
VTRS |
Viatris Inc |
1.13 |
11,232,962 |
|
JAZZ |
Jazz Pharmaceuticals Plc |
1.08 |
10,725,168 |
|
CORT |
Corcept Therapeutics Inc |
0.67 |
6,623,874 |
|
AXSM |
Axsome Therapeutics Inc |
0.66 |
6,585,099 |
|
ELAN |
Elanco Animal Health Inc |
0.33 |
3,262,899 |
|
OGN |
Organon & Co |
0.23 |
2,293,806 |
|
BHC |
Bausch Health Cos Inc |
0.12 |
1,198,619 |
|
PRGO |
Perrigo Co Plc |
0.08 |
781,642 |
|
-USD CASH- |
-- |
0.00 |
7,250 |
|
-- |
Other/Cash |
0.21 |
2,087,282 |
Portfolio
- Market Capitalization (%)
- Currency Exposure (%)
- Sector Weightings (%)
- Country Weightings (%)
Sector Weightings (%) as at 08/31/2026
-
Sector
% of Net Assets -
Health Care
99.79 -
Other/Cash
0.21
Country Weightings (%) as at 08/31/2026
-
Country
% of Net Assets -
United States
63.70 -
United Kingdom
10.90 -
Switzerland
9.98 -
Denmark
4.91 -
France
4.03 -
Israel
3.15 -
Japan
3.12 -
Other/Cash
0.21
Fees
Distributions
as of 09/10/2026
Quarterly
1.89%
2.28%
1.98%
Team
Resources
Regulatory Information
-
Name
Frequency - Annually
- Annually
-
Statement of Additional Information (SAI)
Annually - Annually
- Annually
Fund Documents
-
Name
Frequency -
PPH Fund Profile: A Perfect Prescription for Growth Portfolios
- Daily
-
VanEck Tax Information & Distributions
Annually -
NAV & Premium/Discount History
Daily - Annually
Thought Leadership
-
Name
Frequency